Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of September 2020, with a specific transaction date of September 7, 2020. The report serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director or Manager (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific equity transaction.
| Metric | Value |
|---|---|
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Type | Award of Ordinary Shares under the 2015 Share Value Plan |
| Volume | 6,330 shares |
| Price per Share | £14.96 |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It documents a single share award event.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a standard compliance notification for an insider-related transaction.
Investor Verification Points
- Verify the identity of the PCA (Mr. D. Jackson) and their relationship to the PDMR (Ms. S. Jackson, SVP, Global Communications and CEO Office).
- Confirm the share price of £14.96 aligns with the market price on September 7, 2020.
- Review the terms of the 2015 Share Value Plan to understand the vesting or conditions attached to the 6,330 awarded shares.